ClinicalTrials.gg
Active, not recruitingNCT06537999MOMENTUMUpdated Aug 10, 2026

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

A Phase 2 interventional study of Claseprubart and Placebo in Multifocal Motor Neuropathy, sponsored by Dianthus Therapeutics. Active, not recruiting at 41 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Dianthus Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).

02

Conditions studied

  • Multifocal Motor Neuropathy
03

In context

Lead sponsor

Dianthus Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are carried out
  2. Adult males and females, 18 to 75 years of age (inclusive).
  3. Weight range between 40 to 120 kilograms (kg).
  4. Confirmed diagnosis of definite or probable MMN.
  5. Evidence of:

    1. Responsiveness to Ig treatment; and
    2. Receiving a stable Ig regimen
  6. Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability.
  7. Female participants must be of nonchildbearing potential or if of , must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of .
  8. Male participants must agree not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception or be surgically sterile for at least 90 days prior to Screening.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be or that could impact efficacy assessments.
  2. Any coexisting conditions which may interfere with outcome assessments (eg, severe diabetic neuropathy).
  3. Concurrent or previous use of rituximab, cyclophosphamide, mycophenolate mofetil, azathioprine, or cyclosporine. If a participant has previously used these medications, the last dose must be at least 6 months prior to randomization.
  4. Currently or previously on complement inhibitors including in a clinical trial setting.
  5. Prior history (at any time) of N. meningitidis infection.
  6. Diagnosis of an disorder other than MMN.
  7. Positive test results for active (HIV-1 or HIV-2), surface antigen (HBsAg), or virus (HCV) antibodies during Screening.
  8. History of active within 5 years prior to Screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone.
  9. Participation in another clinical study of an drug within 90 days or 5 half-lives of the investigational agent (whichever is longer) prior to randomization (Day 1).
  10. Any other overlapping condition for which the condition or treatment of the condition may affect the study assessments or outcomes.
  11. Any other condition, including mental illness or prior therapy, that in the opinion of the Investigator would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Claseprubart 300 mg Q2W

    Drug: Claseprubart

  • Experimental
    Claseprubart 600 mg Q2W

    Drug: Claseprubart

Interventions

  • * Day 1: IV loading dose * Week 1 to Week 15: Claseprubart administered SC every 2 weeks

    Also known as: DNTH103

  • DrugPlacebo

    * Day 1: IV infusion of placebo * Week 1 to Week 15: placebo administered SC every 2 weeks

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

    Incidence of treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (SAEs)

    Time frame: Baseline to Week 17

Secondary outcomes

  1. Time to Retreatment With Immunoglobulin (Ig) Since the Final Ig Treatment Before Randomization

    Time between the participant's last dose of Ig and when they require the next dose of Ig after entering the randomized, controlled treatment period of the study

    Time frame: Baseline to Week 17

  2. Time to Clinical Deterioration (CD)

    The time it takes a participant to meet defined criteria for worsening of symptoms in the study

    Time frame: Baseline to Week 17

  3. Mean Value, Mean Change, and Percentage Change From Baseline in Grip Strength

    Grip strength measured in kilopascal (kPa) using a vigorimeter

    Time frame: Baseline to Week 17

  4. Area Under Curve (AUC) of the Change From Baseline in Grip Strength

    Grip strength measured in kPa using a vigorimeter

    Time frame: Baseline to Week 17

  5. AUC of the Change From Baseline in Medical Research Council (MRC)-10 Sum Score

    MRC-10 evaluates motor strength/weakness from a predetermined set of 10 muscle pairs (upper and lower limbs) on a scale of 0 to 5

    Time frame: Baseline to Week 17

  6. Mean Value and Mean Change From Baseline in MRC-10 Sum Score

    MRC-10 evaluates motor strength/weakness from a predetermined set of 10 muscle pairs (upper and lower limbs) on a scale of 0 to 5

    Time frame: Baseline to Week 17

  7. Mean Value and Mean Change From Baseline in MRC-14 Sum Score

    MRC-14 evaluates motor strength/weakness from a predetermined set of 14 muscle pairs (upper and lower limbs) on a scale of 0 to 5

    Time frame: Baseline to Week 17

  8. Mean Value and Mean Change From Baseline in Multifocal Motor Neuropathy Rasch-Built Overall Disability Scale (MMN-RODS) Score

    MMN-RODS consists of 25 items scored on a 3-point scale

    Time frame: Baseline to Week 17

  9. Mean Value and Mean Change From Baseline in Average Time to Complete the 9-Hole Peg Test (9-HPT)

    9-HPT is a quantitative measure of upper extremity (arm and hand) function and dexterity

    Time frame: Baseline to Week 17

  10. Mean Change From Baseline in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    INCAT comprises 2 parts, the arm score and the leg score. Each part is scored between 0 and 5 points, resulting in an INCAT total score between 0 and 10. Adjusted INCAT disability score excludes changes in upper limb function from 0 (normal) to 1 (minor symptoms)

    Time frame: Baseline to Week 17

  11. Mean Change From Baseline in Euro-Quality of Life 5 Dimensions 5 Levels (EQ-5D-5L) Scale

    EQ-5D-5L is comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression

    Time frame: Baseline to Week 17

  12. Mean Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS)

    A vertical VAS is included in the EQ 5D 5L. Participants mark their health status from 0 to 100

    Time frame: Baseline to Week 17

  13. Count and Proportion of Participants With Patient Global Impression of Change (PGIC) Score of Improved or Better

    PGIC is a 7-point scale depicting a participant's rating of overall improvement

    Time frame: Baseline to Week 17

  14. Mean Change From Baseline in Fatigue Severity Scale (FSS) Score

    FSS assesses disabling fatigue in participants with chronic illness

    Time frame: Baseline to Week 17

  15. Mean Change From Baseline in Health-Related Productivity Questionnaire (HRPQ) Outcomes

    HRPQ is a participant diary tool designed to provide data on health-related impacts to labor force participation

    Time frame: Baseline to Week 17

  16. Effectiveness, Side Effects, Convenience, and Overall Satisfaction Scores as Assessed by Treatment Satisfaction Questionnaire for Medications (TSQM)-14

    TSQM-14 is a 14-item treatment satisfaction questionnaire that evaluates the following domains: effectiveness, side effects, convenience, and global satisfaction

    Time frame: Baseline to Week 17

  17. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)

    Incidence of treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (SAEs)

    Time frame: Up to Week 52 of OLE

  18. Serum Concentrations of Claseprubart

    Blood samples will be collected for measurement of serum concentrations of Claseprubart at various timepoints both pre- and post-dose

    Time frame: Baseline to Week 17

  19. Incidence and Titer of Antidrug Antibody (ADA) Levels Against Claseprubart

    Blood samples will be collected to measure ADA against Claseprubart at various timepoints

    Time frame: Baseline to Week 17

07

Study locations

41 sites
  • Clinical Study Site
    Scottsdale, Arizona 85251, United States
  • Clinical Study Site
    Los Angeles, California 90048, United States
  • Clinical Study Site
    Bradenton, Florida 34205, United States
  • Clinical Study Site
    Tampa, Florida 33620, United States
  • Clinical Study Site
    Honolulu, Hawaii 96817, United States
  • Clinical Study Site
    Kansas City, Kansas 66103, United States
  • Clinical Study Site
    Cincinnati, Ohio 45219, United States
  • Clinical Study Site
    Columbus, Ohio 43210, United States
  • Clinical Study Site
    Houston, Texas 77030, United States
  • Cinical Study Site
    Toronto, Canada
  • Cinical Study Site
    Beijing, 100053, China
  • Clinical Study Site
    Beijing, 100730, China
  • Cinical Study Site
    Shanghai, 200031, China
  • Clinical Study Site
    Aarhus, 8200, Denmark
  • Clinical Study Site
    Copenhagen, 1172, Denmark
  • Clinical Study Site
    Marseille, 13005, France
  • Clinical Study Site
    Paris, 94000, France
  • Clinical Study Site
    Rome, 00189, Italy
  • Clinical Study Site
    Kota Kinabalu, 88200, Malaysia
  • Cinical Study Site
    Kuala Lumpur, 50586, Malaysia
  • Cinical Study Site
    Kuala Lumpur, 59100, Malaysia
  • Cinical Study Site
    Permatang Pauh, 13700, Malaysia
  • Cinical Study Site
    Sarawak, 93586, Malaysia
  • Clinical Study Site
    Amsterdam, 1105, Netherlands
  • Clinical Study Site
    Utrecht, Netherlands
  • Clinical Study Site
    Skopje, North Macedonia
  • Clinical Study Site
    Bydgoszcz, 85-090, Poland
  • Clinical Study Site
    Katowice, 40-689, Poland
  • Clinical Study Site
    Krakow, 30-688, Poland
  • Clinical Study Site
    Krakow, 31-202, Poland
  • Clinical Study Site
    Belgrade, 11000, Serbia
  • Cinical Study Site
    Daegu, South Korea
  • Cinical Study Site #2
    Seoul, South Korea
  • Clinical Study Site
    Seoul, South Korea
  • Cinical Study Site
    Alicante, 03010, Spain
  • Clinical Study Site
    Barcelona, 08035, Spain
  • Cinical Study Site
    Barcelona, 08041, Spain
  • Cinical Study Site
    Istanbul, 34093, Turkey (Türkiye)
  • Clinical Study Site
    London, England, United Kingdom
  • Clinical Study Site
    Oxford, England, United Kingdom
  • Clinical Study Site
    Salford, England, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2024
First posted
Aug 5, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Mar 31, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06537999
Lead sponsor
Dianthus Therapeutics
Responsible party
Sponsor
First posted
Aug 5, 2024
Start date
Sep 17, 2024
Primary completion
Dec 2026 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Aug 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Claseprubart

Start the discussion